佛仁制药品牌怎么样 申请店铺

我要投票 佛仁制药在医疗器械行业中的票数:150 更新时间:2025-04-02
佛仁制药是哪个国家的品牌?「佛仁制药」是 甘肃佛仁制药科技有限公司 旗下著名品牌。该品牌发源于陇南市,由创始人曹明月在2004-03-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力佛仁制药品牌出海!通过在本页面挂载佛仁制药品牌的产品链接和联系邮箱,可以提高佛仁制药产品曝光!跨境电商爆单神器,目前只要100元/年哦~

佛仁制药怎么样

甘肃佛仁制药科技有限公司是在收购原甘肃武都制药厂的基础上重新组建的一家股份制企业,主要利用地方特色药材资源,从事中成药产品的生产经营,有40多年的生产历史。2010年1月再次通过了国家GMP认证,是药品生产国家GMP认证企业。具有“国药准字”批准文号的产品46个,其中14个品种是2009年国家新选定的国家基本药物。

公司座落于陇南市武都工业园区,占地面积为43亩,建筑面积为5800平方米,总投资为2745万元,形成固定资产投资1120万元。建有中药材前处理、中药提取、综合制剂和动力维修四个车间,拥有片剂、丸剂、颗粒剂、散剂四条生产线。再建的生产线有胶囊剂、糖浆剂、酊剂、煎膏剂、流浸膏剂,以及中药饮片车间。

安装有35000m3/h风量的空气净化装置,总体净化级别达到了10万级,高出了国家要求。设有新产品开发研究所和产品检验质保中心。公司整体生产设备齐全,检验仪器齐全。年具有生产丸剂1000吨(大蜜丸500吨、水丸320吨、浓缩丸180吨),片剂4亿片、颗粒剂2000万袋、散剂300万袋的生产能力。

企业组织机构健全,人员结构合理。现有职工96人,各类专业技术人员占员工总数的28%。企业通过不断的技术改造,采取新工艺,购置新设备,在努力提高产品质量的同时,以务实诚信为经营理念,企业品牌的建设和产品影响力已初具规模,公司为了更及时快捷的给客户提供服务,特在郑州设立全国营销中心,面向全国进行推广,产品遍及全国各地30多个省市。2013年实现销售收入3000多万元,上缴税金200多万元,预计2014年销售收入可达近5000万元,利税在420万元以上。

甘肃佛仁制药科技有限公司无论是产品的技术优势还是市场优势,都具有广阔的发展前景。我们会把可持续发展战略相关产业链上的工作和包括环境保护在内的各项工作做的更好,为推动地方中药材持续发展,带动药农脱贫致富,解决下岗职工再就业,为人类社会和经济的发展做出应有的贡献。


Gansu Furen pharmaceutical science and Technology Co., Ltd. is a joint-stock enterprise re established on the basis of the acquisition of the former Gansu Wudu pharmaceutical factory. It mainly uses local characteristic medicinal materials resources to engage in the production and operation of Chinese patent medicine products, with a production history of more than 40 years. In January 2010, it passed the national GMP certification again, and is a national GMP certification enterprise for drug production. There are 46 products with the approval number of "Guoyao Zhunzi", 14 of which are national essential drugs newly selected by the state in 2009. The company is located in Wudu Industrial Park, Longnan City, covering an area of 43 mu, a building area of 5800 square meters, with a total investment of 27.45 million yuan, forming a fixed asset investment of 11.2 million yuan. There are four workshops for Chinese medicine pretreatment, Chinese medicine extraction, comprehensive preparation and power maintenance, and four production lines for tablets, pills, granules and powders. The newly built production lines include capsule, syrup, tincture, decocting agent, liquid extract, and herbal pieces workshop. The air purification device with 35000m3 / h air volume is installed, and the overall purification level has reached 100000, which is higher than the national requirements. There are new product development research institute and product inspection and Quality Assurance Center. The company has complete production equipment and inspection instruments. The annual production capacity is 1000 tons of pills (500 tons of honey pills, 320 tons of water pills and 180 tons of concentrated pills), 400 million tablets, 20 million bags of granules and 3 million bags of powder. The organizational structure of the enterprise is sound and the personnel structure is reasonable. At present, there are 96 employees, 28% of which are professional technicians. Through continuous technological transformation, adopting new technology and purchasing new equipment, while striving to improve the quality of products, the company has established a national marketing center in Zhengzhou to provide services to customers in a more timely and efficient manner, with pragmatic and honest business philosophy, and its brand building and product influence has taken shape. Its products are spread all over the country Multiple provinces and cities. In 2013, the company realized sales revenue of more than 30 million yuan and paid taxes of more than 2 million yuan. It is estimated that in 2014, the sales revenue will reach nearly 50 million yuan and the profit and tax will be more than 4.2 million yuan. Gansu Furen pharmaceutical science and Technology Co., Ltd. has broad prospects for development, both in terms of technical advantages and market advantages. We will do a better job in the industry chain related to the sustainable development strategy and in various works including environmental protection, in order to promote the sustainable development of local traditional Chinese medicine, drive pharmaceutical farmers out of poverty and become rich, solve the problem of reemployment of laid-off workers, and make due contributions to the development of human society and economy.

本文链接: https://brand.waitui.com/559930f52.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

加力扩围发力显效,“两新”政策激发消费活力

4月1日,国家发展改革委消息显示,今年前两个月,“两新”政策进一步发力显效,带动设备工器具购置投资同比增长18%,社会消费品零售总额同比增长4%,继续发挥扩消费、稳投资、促转型、惠民生的重要作用。国家发展改革委指出,“两新”政策有效激发了消费活力。今年超长期特别国债支持消费品以旧换新资金规模增加至3000亿元,相较去年的资金规模翻了一番。首批810亿元资金于1月6日第一时间下达,延续2024年工作基础,扩围支持手机、平板、智能手表手环等数码产品购新。(证券时报)

2小时前

2024年中国为欧盟汽车进口最大来源国

4月1日,欧盟发布2024年欧盟汽车行业贸易数据,中国以127亿欧元进口额成为欧盟汽车进口最大来源国,欧方称,2019-2024五年间,欧盟自中国进口汽车增幅高达1591.3%;尽管如此,2024年欧盟对华汽车贸易保持顺差,对华出口高达145亿欧元。2024年,欧盟共出口汽车540万辆,进口汽车400万辆。与2019年相比,出口数量下降了13.2%,进口数量则减少了3.0%。(界面)

2小时前

业绩承诺仅完成6.7%,三鑫医疗高溢价投资面临追偿难

三年累计不低于4200万元的业绩承诺,实际完成280.42万元,完成率仅为6.7%,业绩承诺方暂时无法拿出充足的资金进行股份回购补偿。近日,三鑫医疗一则关于参股公司业绩承诺实现情况专项说明的公告引发众多投资者关注。有受访投行人士分析,高业绩承诺对应的一定是高估值,高估值就意味着高风险,这也提醒上市公司在投资时要紧紧围绕自身战略进行布局,真正做好风险控制。(上证报)

2小时前

全球风险资产震荡,市场静待关税靴子落地

美国即将于4月2日启动对等关税,引发市场连锁反应。美股三大指数上周集体下挫,亚太市场同步承压,避险资金则推动黄金现货价格触及3149.03美元/盎司的历史高位。随着政策实施时点临近,市场对美国经济政策框架的能见度逐步提升。部分机构表示,政策的可预测性上升,积极信号正在酝酿;也有机构对风险资产的表现感到担忧。尽管短期波动性骤增,但市场普遍认为,4月2日将为接下来几个月的金融市场走向定下基调。(中证网)

2小时前

中信建投:电解铝强调清洁能源代替,绿证市场有望加速成长

36氪获悉,中信建投证券研报显示,近期,工业和信息化部等十部门发布关于印发《铝产业高质量发展实施方案(2025—2027年)》。具体来看,《方案》鼓励企业参与光伏、风电等可再生能源和氢能、储能系统开发建设。推进氢氧化铝焙烧、铝用阳极焙烧环节实施清洁能源替代。在我国能耗双控转型的背景下,高耗能企业的清洁用能替代需求有望持续增长,有助于绿电、绿证市场的加速发展,有利于风光项目环境价值的兑现。

2小时前

本页详细列出关于仁和可立克的品牌信息,含品牌所属公司介绍,仁和可立克所处行业的品牌地位及优势。
咨询